Entries by kmaurer

November 13, 2018:

FORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.

September 25, 2018:

FORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.

September 4, 2018:

FORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.

August 29, 2018:

The European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more

August 14, 2018:

Life Science completes its Phase I milestones and receives a Notice of Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more

July 15, 2018:

FORGE Life Science enters into a Sponsored Research Agreement with St. Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J. Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals in ferret models of respiratory infection.

June 18, 2018:

FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.